That big new hy­per­parathy­roidism drug from Am­gen? The FDA re­ject­ed it

Ac­cord­ing to reg­u­lar up­dates from Am­gen over the past two years, in­ves­ti­ga­tors marched through a trio of late-stage stud­ies for etel­cal­ce­tide (AMG416) with noth­ing but …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER